For patients with resectable head and neck cancer, postoperative concurrent chemoradiotherapy has been the standard of care for two decades. With the advent of immunotherapy, this long-established treatment paradigm is undergoing a fundamental transformation, and the integration of perioperative immunotherapy with local treatment has become a major focus of academic discussion.

The plenary sessions of the 29th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) were successfully held in Jinan, Shandong Province, from September 17 to 19, 2026. As CSCO approaches its 30th anniversary, this year's meeting centered on the theme of “Upholding Standards and Embracing Digital and Intelligent Innovation,” focusing on standardized cancer diagnosis and treatment as well as innovation driven by digital and intelligent technologies.

Translating evidence from clinical trials into routine clinical practice involves multiple stages, including translational research, regulatory approval, reimbursement, and adaptation to clinical settings. Overcoming these challenges is a shared priority for the global oncology community.

Breast cancer is one of the most common malignancies among women worldwide. Optimizing screening strategies is essential to improving early detection and reducing mortality. The 2026 Lingnan Breast Cancer Academic Forum was recently held in Guangzhou. At the meeting, Professor Wing Cheong Chow, Medical Director of the Comprehensive Breast Care Centre at Hong Kong Yan Hong Medical Centre, delivered a presentation entitled “Controversies of Breast Cancer Screening Strategies in Asia,” examining the challenges that breast characteristics among Asian women pose for mammography and outlining potential screening approaches. Following the presentation, Oncology Frontier invited Professor Chow to discuss current controversies surrounding the choice of breast cancer screening modalities in Asia, as well as how to balance the risks of overdiagnosis and missed diagnoses.

The 2026 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) was held in Jinan, China. At the meeting, Professor Qiang Wei of the Department of Urology at West China Hospital, Sichuan University, presented a poster based on real-world data from the US Veterans Health Administration (VHA), focusing on patients with newly diagnosed metastatic castration-sensitive prostate cancer (mCSPC) who were older, frail, or had a high burden of comorbidities.

Prostate cancer is one of the most common malignancies among men in China, and its development and progression are closely associated with androgens. Consequently, androgen deprivation therapy (ADT) remains an indispensable cornerstone throughout the prostate cancer disease continuum, from localized disease and metastatic hormone-sensitive prostate cancer to castration-resistant prostate cancer.

Pathological diagnosis is the cornerstone of precision breast cancer care. In recent years, rapid advances in digital scanning, artificial intelligence (AI), and multimodal integration have driven a profound transformation in breast pathology, moving it beyond traditional morphological diagnosis toward a digital and intelligent paradigm. These developments offer new tools and evidence to support precise breast cancer classification, treatment response prediction, and individualized therapy. The 17th Yanzhao Breast Cancer Forum was held in Shijiazhuang from August 26 to 30, 2026. During the meeting, Oncology Frontier invited Professor Hong Bu of West China Hospital, Sichuan University, to discuss the development of digital and intelligent breast pathology, drawing on his presentation entitled “The Development of Digital and Intelligent Breast Pathology.” He shared his insights into the key stages of development, the clinical implementation of AI and human–AI collaboration, the digital transformation of pathology, and its clinical value.

The 17th Yanzhao Breast Cancer Forum was held in Shijiazhuang from August 26 to 30, 2026. Jointly organized by the Beijing Breast Disease Prevention and Treatment Society and the Hebei Clinical Oncology Society, and hosted by the Hebei Provincial Breast Disease Diagnosis and Treatment Center and the Breast Center of the Fourth Hospital of Hebei Medical University, the forum adhered to its guiding principles of “pragmatism, standardization, and development.” It brought together leading breast cancer experts from across China for in-depth discussions on key topics, including surgery, systemic therapy, pathological diagnosis, and multidisciplinary collaboration. During the meeting, Oncology Frontier invited Professor Yunjiang Liu of the Fourth Hospital of Hebei Medical University for an exclusive interview. He shared his insights into breast surgery practices in Hebei Province, the design of training programs in oncoplastic and reconstructive techniques, and strategies for extending these techniques to primary-level hospitals.

The 17th Yanzhao Breast Cancer Forum was held in Shijiazhuang from August 26 to 30, 2026. Continuing the forum's longstanding academic tradition, this year's meeting featured a series of lectures by leading experts from across China, who engaged in in-depth discussions on key topics in breast cancer diagnosis and treatment, as well as specialty development. The multidisciplinary team (MDT) case discussion session was another major component of the forum, focusing on the central role of MDT in the comprehensive management of breast cancer and examining the current status and challenges of extending MDT services to primary-level hospitals. During the meeting, Oncology Frontier invited Professor Zhenchuan Song of the Fourth Hospital of Hebei Medical University to share his insights into the academic highlights of the expert lecture series and specialty development, the core value of MDT in comprehensive patient management, and the challenges and strategies involved in promoting MDT at the grassroots level.